Alliance Between UNC-Chapel Hill and Deerfield intends to advance select Carolina innovations toward a possible new treatment against multiple myeloma
Pinnacle Hill, the research and development partnership between the University of North Carolina at Chapel Hill and Deerfield Management Company, an investment management firm, recently announced its first project agreement to advance the preclinical development of new medicines.
Pinnacle Hill will support a project of Lindsey James, an assistant professor in the UNC Eshelman School of Pharmacy’s chemical biology and medicinal chemistry division. Her work focuses on multiple myeloma, a devastating cancer that develops in bone marrow.
James and her research team are interested in epigenetic abnormalities that lead to cancer and are working to apply medicinal chemistry, chemical biology, and cancer biology approaches to discover potential therapeutic agents. Through this first project, Pinnacle Hill will devote targeted resources to advancing discoveries which have great therapeutic potential for patients with the disease.